Abstract 6006
Background
Elderly patients (pts) with MBC are under-represented in clinical studies and treatment is largely based on limited retrospective subgroup analyses. However, the 3 ESO-ESMO guidelines for Advanced Breast Cancer suggest that the management decisions should not be based on age alone.
Methods
This is an observational, retrospective, multicenter study conducted in 11 Oncology Sicilian Centers that evaluated safety and efficacy of nab-P in pts with HER2 negative MBC with age ≥ 65 years. We included 70 pts. Intrinsic molecular subtype: Luminal A (18.8%), Luminal B HER-2 negative (62.5%) and Triple negative (18.8%). The most common metastatic sites were: visceral plus bone (31.4%), bone (15.7%), lung (10%), visceral plus lymph nodes (10%). 33% of pts received nab-P as 4th line treatment. 87.1% of all pts received nab-P at doses 260 mg/m23-weekly and 12.9% received nab-P 125 mg/m2weekly. 28.6%, 25.7% and 26.2% of pts received previous treatment with taxanes in the neo-adjuvant and metastatic setting, respectively. Primary endpoint was safety of nab-P treatment. Secondary endpoints were overall response rate (ORR), progression free survival (PFS) and overall survival (OS).PFS and OS curves were estimated using the Kaplan-Meier method. ORR was defined as complete or partial response (CR+PR) according to RECIST 1.1 criteria. Adverse events (AEs) were assessed according to CTCAEv4.0.
Results
Median (m) age of pts who received nab-P: 67 years (65-83). mECOG PS: 1 (range 0-2). The m cycles administrated was 6 (range 1-21). 35.5% of pts had a dose reduction and 11.5% of pts had treatment interruptions due to toxicity. The most frequent AEs were G2-3 and were observed in 47% of pts. The main toxicities were fatigue (61.5%), neuropathy (53.8%) and leukopenia (39.1%) and occurred in the 85.7% of pts treated with 3-weekly nab-P. ORR was 31.3% (CR in 6.3% and PR in 25% of pts). 39.1% of pts reported a stable disease. mPFS was 6 months (95% CI 2-38) and mOS was 40.5 months (95% CI 7-255).
Conclusions
Our real-life study showed that the treatment with nab-P is an effective and well-tolerated regimen in MBC elderly pts, even if previously treated with other taxanes. In particular, our data indicate that the weekly nab-P can be safely administered in elderly MBC pts.
Clinical trial identification
Legal entity responsible for the study
Vincenzo Adamo.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract